key: cord-1051197-h61b3bsm
authors: Daniloski, Zharko; Jordan, Tristan X.; Wessels, Hans-Hermann; Hoagland, Daisy A.; Kasela, Silva; Legut, Mateusz; Maniatis, Silas; Mimitou, Eleni P.; Lu, Lu; Geller, Evan; Danziger, Oded; Rosenberg, Brad R.; Phatnani, Hemali; Smibert, Peter; Lappalainen, Tuuli; tenOever, Benjamin R.; Sanjana, Neville E.
title: Identification of required host factors for SARS-CoV-2 infection in human cells
date: 2020-10-24
journal: Cell
DOI: 10.1016/j.cell.2020.10.030
sha: d5bd5615d42dcc3defdb0075fcefd230f5804f13
doc_id: 1051197
cord_uid: h61b3bsm

To better understand host-virus genetic dependencies and find potential therapeutic targets for COVID-19, we performed a genome-scale CRISPR loss-of-function screen to identify host factors required for SARS-CoV-2 viral infection of human alveolar epithelial cells. Top-ranked genes cluster into distinct pathways, including the vacuolar ATPase proton pump, Retromer, and Commander complexes. We validate these gene targets using several orthogonal methods such as CRISPR knock-out, RNA interference knock-down, and small-molecule inhibitors. Using single-cell RNA-sequencing, we identify shared transcriptional changes in cholesterol biosynthesis upon loss of top-ranked genes. In addition, given the key role of the ACE2 receptor in the early stages of viral entry, we show that loss of RAB7A reduces viral entry by sequestering the ACE2 receptor inside cells. Overall, this work provides a genome-scale, quantitative resource of the impact of the loss of each host gene on fitness/response to viral infection.

As of October 2020, SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2), the 2 virus that causes COVID-19, has infected 40 million people worldwide and led to the deaths of 3 more than 1 million people, according to the John Hopkins Research Center (Gardner, 2020) . 4 SARS-CoV-2 belongs to the family of enveloped viruses known as Coronaviridae and was first 5 reported in late 2019 in China. Over the past two decades, it is the third zoonotic coronavirus to 6 emerge: Compared to the other two coronaviruses, SARS-CoV (2002) and Middle East 7 Respiratory Syndrome (MERS)-CoV (2012), SARS-CoV-2 shows an increased infectivity and 8 lower case-fatality rate, contributing to its wide-spread transmission and resulting in a pandemic 9 (Gates, 2020; Liu et al., 2020) . Given that SARS-CoV-2 has already taken a major toll on human 10 life and livelihoods worldwide, many research institutions, governmental organizations and 11 pharmaceutical companies are working to identify antiviral drugs and develop vaccines. 12 Currently, there are nearly 30 vaccines against SARS-CoV-2 in clinical trials and an FDA 13 approved antiviral drug (remdesivir) that acts as an inhibitor of the SARS-CoV-2 viral RNA-14 dependent RNA polymerase (Beigel et al., 2020; Funk et al., 2020) . A recent study identified 15 small molecules that antagonize SARS-CoV-2 replication and infection by testing ~12,000 16 clinical-stage and FDA-approved inhibitors (Riva et al., 2020) . Here, we utilize an alternative 17 approacha genome-scale loss-of-function screento identify targets among host genes that 18 are required for SARS-CoV-2 infection. These gene targets (and inhibitors of these genes) may 19 aid in the development of new therapies for COVID-19. 20 21 SARS-CoV-2 is an enveloped positive-sense RNA virus that relies on host factors for all stages 22 of its lifecycle Zhou et al., 2020) . The viral envelope is coated by Spike 23 protein trimers that bind to angiotensin converting-enzyme 2 (ACE2) receptor, which is required 24 for SARS-CoV-2 infection (Hoffmann et al., 2020a; Zhou et al., 2020) . The Spike protein 25 undergoes proteolytic cleavage that is catalyzed by several host proteases, such as furin, 26 TMPRSS2 and Cathepsin L, and can occur in the secretory pathway of the host cell or during 27 viral entry in the target cell. Proteolytic cleavage is considered to be required for activation of 28 Spike that in turn allows for viral-host membrane fusion and release of the viral RNA into the 29 host cytoplasm (Hoffmann et al., 2020b) . Once in the cytoplasm, the virus utilizes the host and 30 its own machinery to replicate its genetic material and assemble new viral particles. Recent 31 4 proteomic studies have identified hundreds of host proteins that directly bind to SARS-CoV-2 32 viral proteins and have mapped changes in the global protein phosphorylation landscape in 33 response to viral infection, highlighting the interest in better understanding of host-virus genetic 34 dependencies Gordon et al., 2020) . To date, there are no genome-wide 35 studies that directly identify human genes required for viral infection, which will be of great 36 interest and utility for the broader scientific community. 37 38 Here, we perform a genome-scale CRISPR loss-of-function screen in human alveolar basal 39 epithelial carcinoma cells to identify genes whose loss confers resistance to SARS-CoV-2 viral 40 infection. We validate that these genes reduce SARS-CoV-2 infection using multiple orthogonal 

A high-throughput screen to identify genes required for SARS-CoV-2 infection 56 To identify key genes required for SARS-CoV-2 infection, we performed a genome-scale loss-57 of-function screen targeting 19,050 genes in the human genome using the GeCKOv2 CRISPR-58 Cas9 library . The GeCKOv2 library contains 122,411 CRISPR single-59 guide RNAs (6 guide RNAs per gene) and has previously been used in CRISPR screens for drug 60 resistance, immunotherapy, synthetic lethality, mitochondrial disease, and therapeutic discovery 61 for muscular dystrophy (Erb et al., 2017; Jain et al., 2016; Lek et al., 2020; Patel et al., 2017;  62 5 Shalem et al., 2014) . First, we transduced a human alveolar basal epithelial carcinoma cell line 63 (A549) that constitutively expresses ACE2 (referred to as A549 ACE2 ) with an all-in-one lentiviral 64 vector containing Cas9, guide RNAs from the GeCKOv2 human library, and a puromycin 65 resistance gene. The transduction was performed at a low multiplicity of infection (MOI ~ 0.2) to 66 ensure that most cells would receive only one guide RNA construct ( Figure 1A) . We then 67 selected with puromycin so that only library-transduced cells remained. We also measured the 68 survival rate after puromycin selection was complete (3 days) to ensure high coverage of the 69 122,411 guide RNAs (~1,000 cells per guide RNA). After puromycin selection was complete, 70 we cultured the cells for 9 days to ensure protein depletion after CRISPR gene targeting. Figure 1B ) and, at day 6 post-infection, we measured cell survival for both the high and low 76 MOI conditions ( Figure 1C ). As expected, the higher MOI infection resulted in fewer surviving 77 cells at day 6 post-infection. Next, we extracted genomic DNA and, via amplicon sequencing, we 78 quantified guide abundance in each biological condition ( Figure 1A ). To confirm that library 79 representation was properly maintained, we computed the correlation between the guide 80 representation in the plasmid library and after puromycin selection (r = 0.84) ( Figure S1A ). In 81 contrast, after SARS-CoV-2 infection, there was a much greater degree of guide dropout, as 82 expected given that SARS-CoV-2 rapidly kills A549 ACE2 cells without CRISPR perturbations 83 ( Figures 1C, D) . 84 85 Using robust-rank aggregation (RRA) on the guide relative enrichments, we computed gene-86 level scores to identify genes where loss-of-function mutations led to enrichment within the pool 87 ( Figure 1E ) (Kolde et al., 2012) . We identified approximately 1,000 genes with significant RRA 88 enrichment (p < 0.05) ( Figure S1B) . We also used two other previously published methods to 89 compute gene enrichments (RIGER weighted-sum and second-best rank) and found a high 90 degree of overlap between enriched genes identified by all three methods ( Figure S1C ) (Chen et 91 al., 2015; Luo et al., 2008) . We also found a high degree of shared genes across both the low and 92 high SARS-CoV-2 MOI conditions: When examining the top 50 most enriched genes, we found 93 6 that 27 of them were shared between the low and high MOI conditions ( Figure 1F , Table S1), 94 suggesting that several host genes involved in viral pathogenesis function independently of viral 95 dose. An independent genome-scale CRISPR screen for SARS-CoV-2 infection also performed 96 in A549 that overexpress ACE2 but with a different CRISPR library identified similar top-97 ranked genes , highlighting the robustness of our results ( Figure S1D) . 98 Enriched genes are involved in multiple aspects of the viral lifecycle and are broadly expressed 99 Upon close examination of the most enriched genes, we found genes involved in key aspects of 100 viral entry and replication (Figure 2 ) (Du et al., 2009) . For example, the well-established entry 101 receptor angiotensin-converting enzyme 2 (ACE2) receptor was ranked as the 8 th most-enriched 102 gene in the low MOI screen and 12 th in the high MOI screen (Table S1 ) (Hoffmann et al., 2020a; 103 Zhou et al., 2020) . Among the top 50 enriched genes, we identified several sets of related genes 104 that function together in complexes, giving us further confidence in the genome-scale screen 105 (Figures 2 and 3A) . We found genes essential for initial attachment and endocytosis (ACE2, Table S2 ) (Subramanian et al., 2005) . Although we performed our CRISPR screen in human lung cells, we explored whether the 123 expression of host genes whose loss reduces SARS-CoV-2 infection were lung-specific or more 124 broadly expressed. To answer this question, we took the top-ranked genes and examined their 125 expression across 12 tissues using 4,790 RNA-sequencing datasets from the Genotype-Tissue 126 Expression (GTEx) v8 database ( Figure 3C ) (Aguet et al., 2019) . Virtually all of the top gene 127 hits were broadly expressed across all tissues, implying that these mechanisms may function 128 independent of cell or tissue type. Among the top-ranked genes, only ACE2 showed tissue-129 specific expression with a particular enrichment in testis, small intestine, kidney and heart 130 ( Figure 3C) . 131 Enriched genes have been suggested to interact with viral proteins and are also essential for 132 other viral pathogens 133 Recently, Krogan and colleagues performed an in-depth study of SARS-CoV-2 protein-protein 134 interaction networks by over-expressing affinity-tagged versions of each protein encoded in the 135 viral genome followed by tandem mass spectrometry after pulldown (Gordon et al., 2020) . Their 136 study identified 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). 137 We found that some of the highly-ranked genes from our loss-of-function screen were reported 138 to have direct PPI with different viral proteins ( Figure 3D , Table S2 ). For example, two highly-139 ranked subunits of the vacuolar-ATPase proton pump, ATP6AP1 and ATP6V1A, interact with 140 SARS-CoV-2 non-structural protein 6 (nsp6) and membrane (M) protein, respectively. 141 ATP6AP1, which was ranked 2 nd in the low MOI CRISPR screen and 4 th in the high MOI 142 CRISPR screen, has a very strong PPI interaction with nsp6 (Mass spectrometry Interaction 143 Statistics [MIST] score = 0.99) (Verschueren et al., 2015) . Another key endocytosis protein, 144 RAB7A, is ranked in the top 50 genes in both CRISPR screens and interacts strongly with non-145 structural protein 7 (nsp7) (MIST score = 0.97). We also compared the top-ranked genes with 146 another proteomic study that used proximity labeling in A549 cells over-expressing BioID-147 tagged viral proteins and found that 22 out of the top 50 low MOI CRISPR screen genes had 148 direct interactions with viral genesa significant enrichment over randomly chosen genes (p = 149 2 x 10 -4 ) (Samavarchi-Tehrani et al., 2020) . Since similar loss-of-function CRISPR screens have been performed to identify host genes 152 required for other viral pathogens, we next sought to understand whether the hits identified in our 153 8 SARS-CoV-2 screen were shared with those identified in prior screens for Zika virus (ZIKV) 154 and pandemic H1N1 avian influenza (IAV) (Y. Li et al. 2019 . We examined 155 whether top-ranked hits from the ZIKV and IAV screens shared similar genes and similar 156 functional categories. Overall, there was greater similarity between GO categories of enriched 157 genes for SARS-CoV-2 and ZIKV ( Figure 3E ) (Table S2) . When examining the top 50 genes 158 from the SARS-CoV-2 screen, we found several genes that were highly enriched in all 3 viral 159 pathogen screens ( Figure S2E ). This group included subunits of the vacuolar-ATPase proton 160 pump, a well-known family of genes essential for acidification and endosomal processing 161 (Banerjee and Kane, 2020 (Legut et al., 2020) . For a subset of genes, we validated Cas9-mediated loss-of- For these genes, we performed a full multi-step viral replication growth curve and found that the 184 CRISPR perturbations decrease viral load across all timepoints (5, 10, 24 and 48 hours) 185 compared to the non-targeting control ( Figure S3B ). To test if the identified hits block viral 186 infection in other cell lines, for 8 genes we generated polyclonal CRISPR knockouts in a human 187 liver cell line (Huh7.5 ACE2 ), which were then infected with SARS-CoV-2 at an MOI of 0.1. 188 Compared to non-targeting guide RNA controls, we found reduced infection with all 8 genes 189 tested in the Huh7.5 ACE2 cells ( Figure S3C) . 190 191 As an orthogonal gene perturbation method, we also validated a more extensive list of top-192 ranked genes via siRNA knockdown for 48 hours, followed by infection with SARS-CoV-2 at 193 MOI of 0.1 ( Table S3) . Quantification of N-protein immunofluorescent images revealed a 194 substantial reduction of the percent infected cells ( Figure S3D ). 195 196 By cross-referencing highly-ranked genes from the CRISPR screen with the Drug Gene 197 Interaction database (DGIdb), we identified a set of 69 druggable genes ( Figure 4D ) ( Table S4) 198 (Cotto et al., 2018) . We selected 9 genes that were a primary or a secondary target of one of the 199 26 small molecule inhibitors ( Figure 4E ). Among the 26 inhibitors, 9 are FDA approved and 7 200 are in Phase 2 or Phase 3 clinical trials for diverse diseases (Table S4) . We pre-treated A549 ACE2 201 cells for 2 hours with 10 M of each inhibitor and then infected with SARS-CoV-2 and analyzed 202 the cells at 36 hpi. As a positive control, we also included remdesivir, which inhibits the viral 203 RNA polymerase and is the only currently approved treatment for COVID-19 in the United 204 States (Beigel et al., 2020) . We assessed the efficacy of each inhibitor on blocking viral infection 205 using immunofluorescence and quantitative PCR (qPCR). Figure 4E ). Among the best performing inhibitors, 4 of them target the same gene PIK3C3 210 (also known as VPS34) and 2 inhibitors (autophinib and ALLN) reduced the viral load more than 211 1000-fold. Similar results were obtained by immunofluorescent imaging of SARS-CoV-2 N 212 protein ( Figure S4A ). By testing the top four PIK3C3 inhibitors in combination with CRISPR 213 targeting of PIK3C3, we found that Compound-19, PIK-III and autophinib were specific while 214 10 SAR405 resulted in greater viral inhibition in PIK3C3 CRISPR-perturbed cells, suggesting some 215 potential off-target activity for SAR405 ( Figure S4B ).

Combinations of some of the top performing inhibitors overall showed an additive effect and 218 further protected the cells from SARS-CoV-2 infection ( Figure S4C ). Next we measured cell 219 viability at 36 hours post inhibitor treatment using flow cytometry. We observed more than 50% 220 reduction of A549 ACE2 cell viability with two pan-HDAC inhibitors, panobinostat and pracinostat 221 ( Figure 4F) . Table S5) . ECCITE-seq is a high-throughput 230 approach to identify the molecular mechanisms and cellular pathways that drive infection 231 resistance; the pooled format also provides a more controlled experiment that may be less 232 susceptible to batch variation. Importantly, cells were infected at low MOI to maximize the 233 fraction of cells that express a single guide RNA, and therefore can be assigned a specific gene 234 perturbation. For this, we pooled all individual guide RNA plasmids (3 per target gene) used to 235 validate our genome-scale screen and 9 non-targeting (NT) sgRNAs ( Figure 4B ) ( Table S3) . 236 237 In an initial ECCITE-seq experiment, we identified a median of 152 single cells per target gene. 238 We observed specific reduction of target gene expression in cells grouped by target gene, 239 indicating nonsense-mediated decay of transcripts with frameshift indel mutations after CRISPR 240 modification ( Figure S5A ). This effect was more pronounced for genes with higher expression. 241 Using differential gene expression analysis between cells with non-targeting guide RNAs and 242 cells with targeting guide RNAs, we identified for 11 of the 30 target genes more than 5 243 differentially expressed genes with a minimal log fold change (see Methods), implying that loss 244 of these genes results in a detectable transcriptomic shift. It is likely that loss of the other 19 245 11 genes results in more subtle changes in only a few genes; however, even for 'non-perturbed' 246 genes with sufficient basal expression, we detected clear changes in the CRISPR target gene. We To understand how these changes impact lipid production, we measured cholesterol levels in 268 cells after CRISPR perturbation and found that loss of these genes increases cholesterol by 269 between 10 and 50%, depending on the perturbation ( Figure 5D ). To show that increases in 270 cholesterol leads to increased SARS-CoV-2 resistance, we treated A549 ACE2 cells with 271 amlodipine, a calcium-channel antagonist that increases intracellular cholesterol (Mori et al., 272 1988; Ranganathan et al., 1982) . We verified that amlodipine increases cholesterol levels in Rab7a is a small GTPase that is involved in regulating cellular processes such as vesicular 294 transport and membrane trafficking (Guerra and Bucci, 2016) . We hypothesized that the 295 observed reduction of ACE2 at the cell surface in RAB7A knock-out cells may be due to 296 impaired vesicular trafficking and accumulation of ACE2 in the cytoplasm. Immunofluorescence 297 in the A549 ACE2 polyclonal cell line revealed that ACE2 is detected in most cells. We also found 298 that RAB7A knockout leads to an increased accumulation of ACE2 in the cytoplasm and in 299 vesicle-like hollow structures reminiscent of endo-lysosomes ( Figure 6C ). We detected these 300 accumulations in about 35% of RAB7A knockout cells with ACE2 staining, compared to the 301 control where ACE2 was primarily localized at the plasma membrane and small cytoplasmic 302 puncta ( Figure 6D ). Finally, we investigated which cellular compartments accumulate ACE2 in 303 RAB7A knockout cells. Co-immunofluorescence images showed that in RAB7A knockout cells 304 ACE2-containing vesicles often colocalize with EEA1, an early endosomal marker and less 305 frequently with LysoTracker, a lysosome marker ( Figure 6E ).

Since ACE2 was overexpressed in our A549 ACE2 cells, we wondered whether Rab7a loss would 308 lead to similar cytoplasmic sequestration in cells with endogenous ACE2 expression. Flow 309 cytometry analysis in Caco-2 colon and Calu-3 lung cells revealed that RAB7A knock-out cells 310 have significantly reduced cell surface expression of ACE2 compared to cells transduced with a 311 non-targeting guide RNA (Figure 6F , G). We also found that RAB7A knock-out in Caco-2 cells 312 14 results in larger cytoplasmic ACE2 puncta compared to the control cells, further supporting 313 cytoplasmic accumulation of ACE2 in the absence of Rab7a (Figure 6H , I).

Given the current COVID-19 global pandemic, there is an urgent need to better understand the 317 complex relationships between host and virus genetic dependencies. We report a genome-wide 318 loss-of-function screen in human lung cells that identified host genes required for SARS-CoV-2 319 viral infection. We selected and validated 30 genes that were ranked among the top 200 genes. 320 To support the ability of the screen to identify key dependencies, some of the well-known host 321 genes involved in SARS-CoV-2 Spike protein binding and entry such as the ACE2 receptor and 322 Cathepsin L were among the top-scoring genes (Hoffmann et al., 2020a) . One of the validated 323 genes (SIGMAR) encodes the Sigma-1 receptor that was recently identified to be modulated by 324 drugs effective against SARS-CoV-2 in vitro (Gordon et al., 2020) . Overall, the top-ranked and an accumulation in the late endosome/lysosome compartments (Chang et al., 2005; Girard et 339 al., 2014; Millard et al., 2000; Neufeld et al., 1996) . We have recently, in an independent study, 340 identified that SARS-CoV-2 infection negatively downregulates the cholesterol synthesis 341 pathway and that viral infection can be counteracted by drug treatments that upregulate the same 342 15 pathway . It is possible that changes in lipid composition directly impacts 343 SARS-CoV-2 virion maturation and infectivity, as has been previously shown for Hepatitis C 344 and Influenza A (Aizaki et al., 2008; Bajimaya et al., 2017) . In this study, we showed that 345 amlodipine, a calcium-channel antagonist, upregulates cholesterol levels and blocks SARS-CoV-346 2 infection. In addition, recent clinical studies have suggested that patients taking amlodipine or 347 similar dihydropyridine calcium channel inhibitors have a reduced COVID-19 case fatality rate 348 (Solaimanzadeh, 2020; Zhang et al., 2020 ). An important future research direction will be to 349 further understand the relationship between cholesterol synthesis pathways and SARS-CoV-2. A key element in our study was harnessing genome-scale loss-of-function to develop more 377 refined therapeutic hypothesis. Our study suggests that PIK3C3 is a promising drug target: Four 378 out of the seven PIK3C3 inhibitors resulted in more than 100-fold reduction of SARS-CoV-2 379 viral load (SAR405, Compound-19, PIK-III, and Autophinib). Using a PIK3C3 polyclonal 380 knockout A549 ACE2 cell line, we found that among the top four PIK3C3 inhibitors, SAR405 may 381 have some off-target effects ( Figure S4B ). Considering that our polyclonal knockout line likely 382 has some residual PIK3C3, future work will be required to test the inhibitor specificity using a 383 PIK3C3 monoclonal knockout cell line. Another drug that shows a substantial reduction in 384 SARS-CoV-2 viral load is tamoxifen. Tamoxifen is an FDA-approved drug given as prophylaxis 385 to patients at risk of breast cancer and works via modulation of the estrogen receptor. Tamoxifen 386 was included in our study as it targets protein kinase C as a secondary target (O'Brian et al., 387 1985) . This mechanism is further supported by the observation that A549 cells have undetectable 388 transcript levels of estrogen receptor 1 (Human Protein Atlas) (Uhlen et al., 2010) . Considering 389 that tamoxifen is typically given to patients for years as a cancer therapy and prophylactic 390 (Marchant, 1976) , it would be interesting to investigate if patients taking tamoxifen have a 391 reduced risk of SARS-CoV-2 infection and/or display less severe symptoms post-infection. forward-genetics approach allows us to first identify key host genes, which can then be targeted 397 through a diversity of methods such as small-molecule inhibitors, blocking antibodies or gene 398 knockdown. A key advantage of this approach is that the mechanism of action for any 399 therapeutic is well-established from the outset. Percent of A549 ACE2 viable cells following inhibitor treatments at 10 M for 36 hpi determined using LIVE/DEAD stain and flow cytometry. Bars with red hatch marks indicate that inhibitor treatment had a large impact on viability (< 90% viability). Significance testing for panels B, E, and F was performed via a one-way ANOVA with false-discovery rate-corrected follow up tests; for clarity of presentation, all significance testing can be found in Table S6 . Significance testing for panels B and G was performed with a one-way ANOVA (B: F = 9.8, p < 10 -4 ; G:

Calu-3: F = 378, p < 10 -4 , Caco-2: F = 222, p < 10 -4 ) with false-discovery rate-corrected post-hoc tests.

Significance testing for panels D and I was performed with an unpaired t-test. For all panels, * indicates p 

Gating strategy to determine ACE2+ cells. The gate was position such that <3% of A549 wild type and >85% of A549 ACE2 cells were ACE2 positive. The same gating strategy was applied to all samples. C)

Western blot on A549 ACE2 cells perturbed with non-targeting (NT) or RAB7A-targeting guide RNAs and probed with a RAB7A antibody. GAPDH was used as loading control.

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Neville Sanjana (neville@sanjanalab.org).

The pHR-PGK-ACE2 vector generated in this study is available through Addgene (161612). 

Human alveolar basal epithelial carcinoma cells (A549, ATCC CCL-185), human hepatocellular carcinoma (Huh7.5, a kind gift from C. Rice), human colorectal carcinoma (Caco-2, ATCC HTB-37), lung adenocarcinoma (Calu-3, ATCC HTB-55), monkey kidney epithelial cells (Vero E6, ATCC CRL-1586) and human embryonic kidney cells HEK293FT (Thermo) were used in our study. HEK293FT, Huh7.5, and Caco-2 cells were maintained at 37 o C and 5% CO 2 in D10 media, which consists of DMEM (Caisson Labs) with 10% Serum Plus II Medium Supplement (Sigma-Aldrich). Calu-3 and Vero E6 cells were maintained in EMEM (ATCC) media with 10% Serum Plus II Medium Supplement (Sigma-Aldrich) .

SARS-related coronavirus 2 (SARS-CoV-2), isolate USA-WA1/2020 (NR-52281), used in the study (Blanco-Melo et al., 2020; Daniloski et al., 2020) . SARS-CoV-2 was grown in Vero E6 cells in DMEM supplemented with 2% FBS, 4.5 g/L D-glucose, 4 mM L-glutamine, 10 mM non-essential amino acids, 1 mM sodium pyruvate and 10 mM HEPES. Plaque assays were used to determine infectious titers of SARS-CoV-2 by infection of Vero E6 cells in Minimum Essential Media supplemented with 2% FBS, 4 mM L-glutamine, 0.2% BSA, 10 mM HEPES and 0.12% NaHCO 3 and 0.7% agar.

To generate ACE2 expressing cells, the human ACE2 coding sequence was amplified and cloned into the BamHI site of the lentiviral vector pHR-PGK (Addgene 79120). We generated lentiviral particles (as described below) and transduced 5x10 4 A549 cells plated in a 12-well plate in the presence of polybrene (8μg/ml). We confirmed hACE2 expression by western blot analysis (Thermo MA5-32307).

The Human GeCKOv2 A and B libraries (Addgene 1000000048) were used for genome-scale CRISPR knockout screens . We mixed equal amount of the A and B library plasmids to target each gene with 6 guide RNAs. Briefly, 225cm 2 flasks of 80% confluent HEK293FT cells (Thermo) were transfected with 25 g GeCKOv2 plasmid, 14 g pMD2.G and 20 g psPAX2 mixed in 2.5 mL OptiMEM (Thermo) and 175 L Polyethylenimine (1 mg/ml) (Polysciences). After 6 hours, media was changed to D10 media with 1 % bovine serum albumin (Sigma) added to improve virus stability. After 60 hours, viral supernatants were harvested and centrifuged at 3,000 rpm at 4 °C for 10 min to pellet cell debris debris and filtered using 45 m PVDF filters (CellTreat). The supernatant was then ultracentrifuged for 2 hours at 100,000g (Sorvall Lynx 6000) and the pellet resuspended overnight at 4 °C in PBS with 1% BSA.

Following lentiviral titration, 330 million A549 ACE2 expressing cells were transduced at MOI of 0.5. Cells were selected with 2 g/uL puromycin (Thermo) for 12 days to ensure proper selection. Throughout the experiment the representation was monitored such that each guide RNA is represented by at least 1000

We infected GeCKOv2-transduced cells (~1000x representation) with SARS-CoV-2 isolate USA-WA1/2020 (NR-52281) at either MOI of 0.01 (low MOI) and 0.3 (high MOI). Surviving cells were collected on day 6 post-infection for genomic DNA isolation.

We used a two-step PCR protocol (PCR1 and PCR2) to amplify the guide RNA cassette for Illumina sequencing from genomic DNA (gDNA). The gDNA was extracted from CRISPR screen cells using the following protocol (Chen et al., 2015) : Per 100 million cells, 12 mL of NK Lysis Buffer (50 mM Tris, 50 mM EDTA, 1% SDS, pH 8) were used for cell lysis. Once cells were resuspended, 60 µL of 20 mg/ml Proteinase K (Qiagen) was added and the sample was incubated at 55ºC overnight. The next day, 60 µL 27 of 20 µg/mL RNase A (Qiagen) was added, mixed, and samples were incubated at 37ºC for 30 min. Then 4 mL of pre-chilled 7.5 M ammonium acetate was added, samples were vortexed and spun at 4,000g for 10 min. The supernatant was placed in a new tube, mixed well with 12 mL isopropanol and spun at 4,000g for 10 min. DNA pellets were washed with 12 mL of 70% ethanol, spun, dried and pellets were resuspended with 0.2x TE buffer (Sigma).

For the first PCR reaction, we used all gDNA available for each sample. We performed the PCR1 using Taq-B polymerase (Enzymatics) and used multiple reactions where each reaction contained up to 10 g gDNA per 100 L PCR reaction. PCR1 products for each sample were pooled and used for amplification with barcoded PCR2 primers. For each sample, we performed 12 PCR2 reactions (using 5 µL of the pooled PCR1 product per PCR2 reaction) with Q5 polymerase (NEB). PCR2 products were pooled and then normalized within each biological sample before combining uniquely-barcoded separate biological samples. The pooled product was then gel-purified from a 2% E-gel EX (Life Technologies) using the QiaQuick gel extraction kit (Qiagen). The purified, pooled library was then quantified with Tapestation 4200 (Agilent Technologies). PCR products were run on a 2% agarose gel and the correct size band was extracted. Sequencing was performed on the NextSeq 550 instrument using the HighOutput Mode v2 with 75 bp paired-end reads (Illumina). All PCR1 and PCR2 primer sequences, including full barcodes, are listed on the GeCKO website (http://genome-engineering.org/gecko/). Sequencing reads were demultiplexed upon sequencing based on Illumina i7 barcodes present in PCR2 reverse primers using Illumina BaseSpace. We performed adaptor trimming by treating the hU6 promoter sequence as a 5' adapter, using cutadapt v1.13 [-e 0.2 -O 5 -m 20 -g TCTTGTGGAAAGGACGAAACACCG]. Processed guide RNA sequences were aligned to the GeCKOv2 reference allowing for up to 1 mismatch using bowtie v1.1.2 [-a --best --strata -v 1norc] with alignment rates of 81% to 86%.

Guide RNA counts were processed using the MaGeCK pipeline with an output of RRA p-values and gene ranks (Chen et al., 2018) . We separately ranked genes using the RIGER (weighted-sum) and second-best rank methods (Chen et al., 2015; Luo et al., 2008) . Gene Set Enrichment Analyses were performed using the fgsea package with Gene Ontology for biological processes (c5.bp.v7.1.symbols) (Korotkevich et al., 2019) . GTEx v8 tissue specific enrichment was performed using the Multi Gene Query function available on the GTEx website: https://www.gtexportal.org/home/multiGeneQueryPage (accessed August 1st, 2020) (Aguet et al., 2019) . GO enrichments for SARS-CoV-2, ZIKV, and IAV CRISPR screens were performed using GOrilla to find all significant enrichments (FDR p-value < 10-28 3) (Eden et al., 2009) . FDR p-values were log 10 -transformed and normalized to create the heatmap shown in Figure 3E .

For validation by CRISPR knock-out (using 3 independent guide RNAs per gene), we selected genes that were highly-ranked (either in the low or high MOI screen or both) or genes that had not previously been implicated in viral pathogenesis or immune signaling. For each gene of interest, 3 guide RNAs were designed using GUIDES software and were subsequently cloned into an all-in-one vector with an optimized Cas9 scaffold (pCC_01, Addgene 139086) containing Cas9, a guide RNA cassette and a puro resistant cassette (Legut et al., 2020; Meier et al., 2017) . Following sequence confirmation by Sanger sequencing, lentivirus was produced individually for each plasmid and the target cells were transduced in presence of polybrene (10 g/mL, Santa Cruz). Gene-perturbed A549 ACE2 , Huh7.5 ACE2 , Calu-3 and Caco-2 cells were selected for at least 10 days with 2 g/mL (A549 ACE2 , Calu-3), 3 g/mL (Caco-2) or 5 g/mL (Huh7.5 ACE2 ) puromycin (Thermo). To determine the SARS-CoV-2 infection susceptibility of geneperturbed lines, 10,000 cells were plated per well of 96-well plates. After 24 hours, the cells were infected with SARS-CoV-2 at MOI of 0.1. At 36 hours post-infection, the cells were either fixed and processed for immunofluorescence or cellular RNA was harvested for qRT-PCR analyses. For the multistep growth curves, cells were infected at an MOI of 0.1, and total RNA was harvested from infected cells at indicated times. RNA was processed for qRT-PCR as described above. All infections with SARS-CoV-2 were performed with at least 3 biological replicates.

Cells were fixed with 5% formaldehyde and immunostained for nucleocapsid (N) protein and visualized with a secondary antibody labeled with AlexaFlour-568 (Thermo). SARS-CoV-2 nucleocapsid (N) antibody (clone 1C7C7) was obtained from the Center for Therapeutic Antibody Discovery at the Icahn School of Medicine at Mount Sinai. Nuclei were stained with DAPI. Full wells were imaged and quantified for SARS-CoV-2 infected cells using a Celigo imaging cytometer (Nexcelom Biosciences). All infections with SARS-CoV-2 were performed with 3 biological replicates. Representative images from the top gene knockout hits were acquired using the EVOS M5000 Imaging System (Thermo).

To identify druggable genes among the top CRISPR screen hits, we cross-referenced highly-ranked genes from the RRA analysis with the data table containing drugs and their gene targets was obtained from Drug Gene Interaction database (DGIdb, retrieved on June 3, 2020) as well as manual literature search 29 (Cotto et al., 2018) . Inhibitors that target the genes of interest (and remdesivir) was obtained from SelleckChem and MedChemExpress. The catalog number and vendor information is available in the Key Resource section. Amlodipine was obtained from Sigma (A5605).

To test drug efficacy in reducing SARS-CoV-2 infection, 10,000 A549 ACE2 cells were seeded per well of a 96-well plate. Cells were treated with inhibitors at 10 M for two hours before infection and inhibitors were maintained throughout the course of infection. Cells were infected with SARS-CoV-2 at MOI of 0.1 for 36 hours and the cells were collected for analysis via qRT-PCR or processed for immunofluorescence (N protein and quantified by Celigo). For Figure 4E , the remdesivir data was collected in an independent experiment.

Cell viability following drug treatments was performed the same way as described above. Thirty-six hours post drug treatment the cells were collected and stained with LIVE-DEAD Violet (Thermo). Cell acquisition was performed using a Sony SH800S cell sorter with a 100 m sorting chip. We used the following gating strategy: 1) We excluded the cell debris based on the forward and reverse scatter; 2) Doublets were excluded by plotting FSC height vs FCS area, 3) Dead cells were quantified using livedead violet stain. For all samples, we recorded at least 5,000 cells that pass the gating criteria described above. Flow cytometry analyses were performed using FlowJo v10. Cell viability for A549-ACE2 treated with DMSO or 10µM amlodipine was performed 24 hours post treatment using Trypan Blue (Thermo Fisher) and automated cell counting (Nexcelom AutoT4).

RNA was extracted from cells grown in 96-well plates by using the RNeasy 96 Kit (Qiagen) per the manufacturer's instructions. RNA was reverse-transcribed and PCR amplified using SYBR Fast One-step Universal qRT-PCR Kit (KAPA/Roche). For amlodipine experiments, RNA was extracted using TRIzol Reagent (Invitrogen) and purified with the Direct-zol RNA Miniprep kit (Zymo Research) as per the manufacturer's instructions (including the optional DNase I treatment). For amlodipine experiments, the RNA was reverse-transcribed using SuperScript Reverse Transcriptase II (Thermo Fisher) and oligo(dT) primers. The cDNA was diluted 1:20 before qRT-PCR was performed using SYBR Fast qPCR (KAPA/Roche). SARS-CoV-2 replication was assessed by using primers specific to the N mRNA (Forward 5'-CTCTTGTAGATCTGTTCTCTAAACGAAC-3'; Reverse 5'-GGTCCACCAAACGTAATGCG-3').

SARS-CoV-2 N mRNA levels were normalized to beta tubulin (Forward 5'-GCCTGGACCACAAGTTTGAC-3; Reverse 5'-TGAAATTCTGGGAGCATGAC-3'). Reactions were ran and analyzed on a Lightcycler 480 II Instrument (Roche). Relative quantification was calculated by 30 comparing the cycle threshold (C t ) values using C t . C t values of subgenomic nucleocapsid transcript were normalized to C t values of alpha-tubulin, and those values were normalized to viral transcript levels of DMSO-treated or non-targeting guide RNA-transduced control samples, and displayed as foldreduction in viral transcript. Significance was determined using a one-way ANOVA with post-hoc tests or a two-tailed unpaired Student's t-test, as appropriate.

All of the siRNAs were ordered from Dharmacon and their catalog number can be found in the Key Resource Table. To knockdown individual genes, 10,000 A549 ACE2 cells were seeded in 96-well plates and transfected with siRNAs using Lipofectamine RNAiMAX (Thermo) following the manufacturer's protocol. Forty-eight hours later, the cells were infected with SARS-CoV-2 at an MOI of 0.1 for 36 hours.

Cells were fixed with 5% formaldehyde, stained with nucleocapsid protein (clone 1C7C7, ISMMS), and visualized with AlexaFluor-568 conjugated secondary antibody (Thermo). Nuclei were stained with DAPI, and full wells were imaged with a Celigo imaging cytometer (Nexcelom Biosciences).

To generate the minipool, we combined equimolar amounts the same guide RNA vectors (cloned in pCC1) that we used for arrayed validation (see above Generation of gene-perturbed A549 ACE2 lines and SARS-CoV-2 infection). In total, we combined 3 guide RNAs for each gene (either, 30 or 11 genes) plus 9 non-targeting guide RNAs. The non-targeting guide RNA plasmids were added at half the molar ratio of the other plasmids. Lentivirus was produced via transfection of the minipool with appropriate packaging plasmids (psPAX2: Addgene 12260; pMD2.G: Addgene 12259) using polyethylenimine (PEI) reagent in HEK293FT. The target A549 ACE2 cells were transduced in presence of polybrene (10 g/mL, Santa Cruz) (ECCITE-Seq experiment 1) or without (ECCITE-seq experiment 2) at very low MOI to ensure entry of a single virus per cell. The survival was below 5% after 2 days of selection with 2 g/mL puromycin (Thermo) for both ECCITE-seq experiments. On day 10 post-transduction, the cells were collected and processed for ECCITE-seq.

To perform cell-hashing and ECCITE-seq Stoeckius et al., 2018) , we separated cells into several sub-pools and, for each pool, we resuspended 1 million cells in 100 µl staining buffer (2% BSA, 0.01% Tween in PBS). We then added 10 µl Human TruStain FcX Fc Receptor Blocking Solution (BioLegend) and incubated on ice for 10 minutes. We then added hashing antibodies (BioLegend), incubated on ice for 30 minutes, and washed cells 3 times with staining buffer. In total, we 31 ran four lanes of a Chromium Single Cell Immune Profiling Solution v1.0 5' kit (10x Genomics) targeting recovery of 12,000 cells per lane (superloading) in experiment 1 and 20,000 cells in experiment 2. Gene expression (mRNA), hashtags (Hashtag-derived oligos, HTOs) and guide RNA (Guide-derived oligos, GDOs) libraries were constructed . Each replicate was sequenced on two NextSeq550 75-cycle high-output runs (Illumina). Sequencing reads from the mRNA library were mapped to the hg38 reference genome (Ensembl v97) using Cellranger (v3.0.1, 10x Genomics). To generate count matrices for HTO and GDO libraries, the CITE-seq-count package was used (https://github.com/Hoohm/CITE-seq-Count v1.4.2). Count matrices were then used as input into the Seurat R package (v3.2) for downstream analyses (Stuart et al., 2019) .

Processing of initial ECCITE-seq experiment with 30 target genes: Cells with low quality metrics, high mitochondrial gene content (> 17.5%) and low number of genes detected (≤ 1800) were removed. The median number of detected genes was 3309. RNA counts were log-normalized and HTO counts were normalized using the centered log-ratio transformation approach, with margin=2 (normalizing across cells). To identify cell doublets and assign experimental conditions to cells, we used the HTOseqDemux function (Stoeckius et al., 2018) . HTOseqDemux-defined cell doublets and negatives were removed from any downstream analyses. Cellular guide RNA identity for cells in the ECCITE-seq pool was assigned based on GDO unique molecular identifier (UMI) counts. We considered a guide RNA detected with ≥ 16 UMI counts (the median UMI counts per guide RNA was 503 counts, 93% of cells with ≥ 1 sgRNA). We observed that 64% of the cells had >1 detected guide RNA (29% 1 guide RNA, 27% 2 guide RNAs, 17% 3 guide RNAs). To maximize cell recovery, we retained cells with 1 -3 guide RNAs per cell (n = 10,265). We collapsed the guide RNA information down to target gene level (3 guide RNA per target gene) in the following way: For all cells (with 1-3 guide RNAs), we assigned a unique target gene if all detected guide RNAs targeted the same gene, or if the additional guide RNA detected was a non-targeting (NT) guide RNA (4,715 cells: 4,013 cells with exactly 1 sgRNA and 702 cells with collapsed target gene assignment). All remaining cells assigned 2 or 3 separate target genes were discarded.

Some of the top-ranked genes from the CRISPR screens may be endpoint genes and thus may have subtle phenotypes difficult to detect using single-cell transcriptomics. To address this issue, we used the initial ECCITE-seq experiment (n = 4,715 cells) and grouped cells by target gene. To identify target gene perturbations that lead to systemic transcriptomic changes, we determined the number of differentially expressed genes relative to cells with NT guide RNAs. We found that under stringent filtering conditions 32 (non-adjusted p-value < 10 -5 or adjusted p-value < 0.2), only 11 target genes showed more than 5 differentially expressed genes. The second ECCITE-seq experiment was conducted using guide RNAs solely for these.

Cells with low quality metrics, high mitochondrial gene content (> 15%) and low or high number of genes detected (≤ 2000 and > 5000) were removed. The median number of detected genes was 3365, with a median of 13,532 UMIs per cell. HTO counts were normalized using the centered log-ratio transformation approach, with margin=2 (normalizing across cells). To identify cell doublets and assign experimental conditions to cells, we used the HTOseqDemux function (Stoeckius et al., 2018) . HTOseqDemux-defined cell doublets and negatives were removed from any downstream analyses. Guide RNA counts were normalized similar to HTO UMI counts. Cell-wise guide RNA assignment was achieved using the MultiSeqDemux function (McGinnis et al., 2019) . We only retained cells assigned with a single HTO and a single guide RNA (ECCITE-seq experiment 1: n = 1,824 cells, ECCITE-seq experiment 2: n = 17,029 cells). Cells from ECCITE-Seq experiment 1 and experiment 2 were harmonized by log-normalizing, followed by the identification of the 2000 most variable features with "vst" selection method. Next, we we used FindIntegrationAnchors and IntegrateData with the first 40 principle components.

In the harmonized data set (n = 18,853 cells), we used FindMarkers to find differentially expressed genes between non-targeting cells and cells that belonged to a targeted gene class. We used up to 100 of the most upregulated genes with adjusted p-value < 0.01 and minimal log e FC threshold > 0.1 filter as input into the heatmap in Figure 5B . The same FindMarkers analysis (but using the non-adjusted pvalue < 0.01 with a maximum of the 300 most significant DEGs) was used as input into the EnrichR package to run pathway analysis using the human WikiPathways database (v. 2019) (Kuleshov et al., 2016; Slenter et al., 2018) . Figure 5C shows -log 10 transformed p-values for the union of all enriched pathways with an adjusted p-value < 0.01 across the 11 target genes with perturbation signatures.

Infectious titer in supernatant of SARS-CoV-2 infections (from A549 ACE2 ) was determined by plaque assay in Vero E6 cells. Cells were seeded in 12-well plates before infection with logarithmically diluted supernatants in a total inoculum of 100 ul, rocking plates every 10 minutes for 1 hour. Then an overlay of Minimum Essential Media with 0.12% NaHCO3, 4 mM L-glutamine, 0.2% BSA, 10 mM HEPES and 0.7% OXOID agar (Thermo) was aliquoted into wells and plates were incubated for 48 hours before fixing with 5% formaldehyde. After 24 hours, plaques were stained with crystal violet (1% crystal violet in 20% EtOH) for 15 minutes before washing wells and counting plaques.

Bulk RNA-sequencing RNA-sequencing libraries were constructed from 1ug of RNA per sample using the TruSeq Stranded mRNA Library Prep Kit (Illumina) according to the manufacturer's instructions. Sequencing libraries were sequenced using an Illumina NextSeq 500 platform and fastq files were generated using bcl2fastq (Illumina). Alignment to the SARS-CoV-2 genome (GenBank: MN985325.1) were performed using bowtie (Langmead et al., 2009) . Reads were aligned to hg19 using STAR aligner in the Basespace RNA-Seq Alignment application (Illumina) and processed using DESeq2 (Love et al., 2014) . Sample distances were calculated using read counts from the regularized log transform in DESeq2.

K-means clustering was perfomed using the kmeans function in R/RStudio. Enriched Reactome pathways were identified using the STRING tool (Szklarczyk et al., 2019) .

Cellular cholesterol was measured using the Cholesterol-Glo assay (Promega). For each cell line (CRISPR-perturbed or drug-treated), we counted 100,000 cells, washed with 1xPBS twice and resuspended in 100 L cell lysis solution for 30 min at 37°C. Following the incubation, 10 L of cell lysate was used to measure the cholesterol levels in 96 well plates in a final reaction volume of 100uL per well (without esterase). Luminescence was measured after incubating the plate for 1 hour at room temperature in the dark. Using the same lysis sample, the protein concentration was determined using the BCA assay (Thermo). The cholesterol levels were normalized to the respective protein concentration of each sample. A549 ACE cells were incubated with 10 M amlodipine (Sigma) or DMSO for 24 hours.

Cholesterol levels were then determined as described above.

Cells were harvested, counted and about 100,000 cells were washed with Dulbecco's phosphate-buffered saline (PBS, Caisson Labs) and then stained with LIVE/DEAD Violet stain (Thermo, 34864). Following a wash with 1x PBS, all subsequent washes and antibody dilutions were performed using 1x PBS supplemented with 2% FBS. Wild-type or Cas9-perturbed A549 ACE2 , Caco-2 and Calu-3 cells were stained for 30 min on ice with 0.25 g of anti-ACE2 antibody (R&D Systems, AF933) in ~50 L residual volume. Following two washes with 1x PBS with 2% FBS, samples were stained on ice for 20 min with 7.5 L of anti-goat-APC secondary antibody (R&D Systems, F0108). Cell acquisition and sorting was performed using a Sony SH800S cell sorter with a 100 m sorting chip. We used the following gating strategy: 1) We excluded the cell debris based on the forward and reverse scatter; 2) Doublets were excluded by plotting FSC height vs FCS area, 3) Dead cells were excluded by live-dead stain. We recorded at least 5,000 cells for A549 ACE2 and at least 3,000 cells for Calu-3 and Caco-2 that pass the 34 gating criteria described above. Gates to determine ACE2-APC+ cells were set based on control A549 wild type cells or only secondary antibody stained Calu-3 and Caco-2, where the percent of ACE2 positive cells was set as <5% (background level). Flow cytometry analyses were performed using FlowJo v10.

Immunofluorescence of ACE2 and endo/lysosomal markers A549 ACE2 Cas9-transduced (specific gene or non-targeting) cell lines were seeded on poly-D-lysinecoated coverslips (Electron Microscopy Sciences) 24 hours before they were fixed with 4% formaldehyde (Sigma) diluted in 1x PBS (Caisson Labs) . Following 3 washes with 1x PBS, cells were blocked with 1x PBS with 2% BSA for 30 min at room temperature. Cells were stained with mouse anti-2A antibody diluted at 1:250 (clone 3H4, Millipore Sigma, MABS2005) to recognize ACE2-2A, and rabbit anti-EEA1 diluted at 1:100 (Thermo, MA5-14794). To detect ACE2 in Caco-2 cells, goat anti-ACE2 (R&D Systems, AF933) was used at 1.25 g/mL. Cell were incubated with primary antibodies for 3 hours at room temperature in a moisturized chamber. Coverslips were then washed 5 times with 1x PBS with 2% BSA and then incubated with Alexa-conjugated secondary antibodies (Jackson ImmunoResearch) diluted at 1:1000 for 45 min at room temperature. Coverslips were then washed 5 times with 1x PBS with 2%BSA, and DAPI (Sigma) was added in the fourth wash at a concentration of 0.1 g/mL. To stain the lysosomes, LysoTracker DeepRed (Thermo) was diluted to 70 nM in culture media and was added to actively growing cells on coverslips and were incubated for 1 hour at 37C.

Following incubation with LysoTracker, cells were processed for immunofluorescence as described above. Confocal images were acquired on a Zeiss LSM 780 with a 20x/0.8 Plan-Apochromat objective or a 63x/1.4 Plan-Apochromat objective (Zeiss). Epifluorescence images were acquired using the same system; both fitted with a Zeiss Axiocam 506 mono (Zeiss). Images were processed using Zen Black 2012 (Zeiss) and FIJI 2.1.0; Java 1.8.0-202 (Schindelin et al., 2012) . Linear histogram adjustments were applied uniformly within experiments for clarity of presentation.

ACE2 localization was determined on images taken on a Zeiss LSM 780 with a 20x/0.8 Plan-Apochromat objective using Zen Black (Zeiss). The A549 ACE2 polyclonal cell line had both ACE2 positive and negative cells. Only ACE2 positive cells were then manually scored if they had a distinct accumulation of cytoplasmic vesicles-like hollow structures, compared to the non-targeting (NT) control. In the NT control, the ACE2 staining was seen on the plasma membrane and diffuse in the cytoplasm. The scoring was performed on 2 biological replicates (that is, two separate non-targeting controls and two separate Rab7A knockout lines engineered using 4 separate Cas9 guide RNAs). We scored ~430 cells per replicate. To quantify the size of ACE2 foci, confocal microscopy images were thresholded using FIJI's 35 local-threshold (Phansalkar radius = 15) and then a watershed transform was applied. Foci were counted and measured using FIJI's Analyze Particles function.

A549 ACE2 or Huh7.5 ACE2 cells were collected, washed with 1x PBS and lysed with TNE buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Nonidet P-40) in presence of protease inhibitor cocktail (Bimake B14001) for 1 hour on ice. Cells lysates were spun for 10 min at 10,000 g, and protein concentration was determined with the BCA assay (Thermo). Equal amounts of cell lysates (20g) were denatured in Tris-Glycine SDS Sample buffer (Thermo LC2676), and loaded on a Novex 4 -20% Tris-Glycine gel (Thermo XP04205BOX). PageRuler pre-stained protein ladder (Thermo 26616) was used to determine the protein size. The gel was run in 1x Tris-Glycine-SDS buffer (IBI Scientific IBI01160) for about 120 min at 120V. Proteins were transferred on a nitrocellulose membrane (BioRad 1620112) in presence of prechilled 1x Tris-Glycine transfer buffer (FisherSci LC3675) supplemented with 20% methanol for 100 min at 100V. Immunoblots were blocked with 5% skim milk dissolved in 1x PBS with 1% Tween-20 (PBST) and incubated overnight at 4C separately with the following primary antibodies: rabbit anti-RAB7A (0.1g/mL, NovusBio, NBP1-87174), rabbit anti-GAPDH (0.1 g/mL, Cell Signaling, 2118S), rabbit anti-CCDC22 (0.34 g/mL, Proteintech, 16636-1-AP), rabbit anti-ATP6V1A (0.46 g/mL, Proteintech, 17115-1-AP), rabbit anti-ACE2 (0.5 g/mL, Invitrogen, MA5-32307), and mouse anti-beta tubulin (0.5 g/mL, Invitrogen, 32-2600). Following the primary antibody, the blots were incubated with IRDye 680RD donkey anti-rabbit (0.2 g/mL, LI-COR 926-68073) or with IRDye 800CW donkey anti-mouse (0.2 g/mL, LI-COR 926-32212). The blots were imaged using Odyssey CLx (LI-COR).

Statistical parameters and details are reported in each figure legend. Generally, experiments were repeated with at least three biological replicates. Each plot includes points for individual biological replicates and mean ± s.e.m. error bars unless otherwise specified. In general, biological replicates consist of replicate viral transductions (CRISPR), replicate RNA transfections (siRNA), or replicate drug treatments (small molecule inhibitors) and are specified in each figure legend. For imaging experiments, the number of cells scored per biological replicate is given in the figure legend. 36 When assessing significance of genetic perturbations and/or inhibitor treatments, we employed first a oneway or two-way ANOVA to assess significance and, when significant, post-hoc comparisons were performed using the false-discovery rate method of Benjamini-Krieger-Yekutieli to correct for multiple comparisons. Before applying ANOVA, we first verified the equality of group variances using the Brown-Forsythe test. Details for all ANOVA and post-hoc multiple comparisons are reported in Table   S6 ; t-tests are reported in the respective figure legends.

Throughout the manuscript, we use r to denote the Pearson correlation and r s to denote the Spearman correlation; all reported correlations were significant using the cor.test function in R. For the BioID interactome analysis, we derived an empirical p value by resampling from a null distribution (n = 10,000 gene shuffling iterations). Statistical analyses were performed in GraphPad Prism 8 and RStudio Tables   Table S1 . SARS-CoV-2 pooled CRISPR screen ranked gene lists for low and high MOI screens, Related to Figures 1 and S1. To identify potential therapeutic targets for SARS-CoV-2, Daniloski et al. conduct a genome-wide CRISPR screen in human lung epithelial cells. They identify genes and pathways required for SARS-CoV-2 infection, including the vacuolar ATPase proton pump, Retromer, and Commander complexes. Using single-cell transcriptomics, they identify upregulation of cholesterol biosynthesis as a common mechanism underlying viral resistance, in addition to ACE2 sequestration.

Genome-scale CRISPR knock-out in human A549 ACE2 cells

Gene rank Non-targeting RAB7A  CCDC22  VPS35  SNX27  CTSL  ATP6AP1  ACE2  PIK3C3  COMMD3  HNRNPC  ATP6V1A  TMPRSS2  NPC1  HDAC9  CNOT4  BAX  INO80E  ZC3H18  TMEM165  TMPRSS13  FBXO33  FBXO27  TOR1AIP1  CXCL5  SIGMAR1  TRIM4  PCID2  PSMB5  SPEN **** **** **** ****

The GTEx Consortium atlas of genetic regulatory effects across human tissues

Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection

Cholesterol is required for stability and infectivity of influenza A and respiratory syncytial viruses

Regulation of V-ATPase Activity and Organelle pH by Phosphatidylinositol Phosphate Lipids

Remdesivir for the Treatment of Covid-19 -Preliminary Report

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Niemann-Pick type C disease and intracellular cholesterol trafficking

Improved design and analysis of CRISPR knockout screens

Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis

DGIdb 3.0: a redesign and expansion of the drug-gene interaction database

The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists

Transcription control by the ENL YEATS domain in acute leukaemia

A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic

Johns Hopkins Coronavirus Resource Center

Responding to Covid-19 -A Once-in-a-Century Pandemic?

Rab7 is functionally required for selective cargo sorting at the early endosome

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Multiple Roles of the Small GTPase Rab7

SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2

Modulating the transcriptional landscape of SARS-CoV-2 as an effective method for developing antiviral compounds

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Hypoxia as a therapy for mitochondrial disease

The Architecture of SARS-CoV

Robust rank aggregation for gene list integration and metaanalysis

Fast gene set enrichment analysis

Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

Highthroughput screens of PAM-flexible Cas9 variants for gene knock-out and transcriptional modulation

Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy

Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection

Genome-wide CRISPR screen for Zika virus resistance in human neural cells

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Highly parallel identification of essential genes in cancer cells

Systems-wide Studies Uncover Commander, a Multiprotein Complex Essential to Human Development

Letter: Prophylactic chemotherapy for breast cancer

MULTI-seq: sample multiplexing for single-cell RNA sequencing using lipid-tagged indices

Endosomal Retrieval of Cargo: Retromer Is Not Alone

GUIDES: sgRNA design for loss-of-function screens

Niemann-pick type C1 (NPC1) overexpression alters cellular cholesterol homeostasis

Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells

Effects of calcium antagonists on low density lipoprotein metabolism in human arterial smooth muscle cells

Intracellular trafficking of cholesterol monitored with a cyclodextrin

Inhibition of protein kinase C by tamoxifen

Identification of essential genes for cancer immunotherapy

Effect of Ca2+ blocking agents on the metabolism of low density lipoproteins in human skin fibroblasts

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

RAB7 and TSG101 are required for the constitutive recycling of unliganded EGFRs via distinct mechanisms

A SARS-CoV-2 -host proximity interactome

Improved vectors and genome-wide libraries for CRISPR screening

Fiji: an open-source platform for biological-image analysis

Genome-scale CRISPR-Cas9 knockout screening in human cells

WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research

ECCITE-seq

Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19

Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics

Comprehensive Integration of Single-Cell Data

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

Towards a knowledge-based Human Protein Atlas

Scoring Large-Scale Affinity Purification Mass Spectrometry Datasets with MiST

Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection

Calcium channel blocker amlodipine besylate is associated with reduced case fatality rate of COVID-19 patients with hypertension

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The S1/S2 boundary of SARS-CoV-2 spike protein modulates cell entry pathways and transmission

We thank the entire Sanjana and tenOever laboratories for support and advice. We also thank the New York Genome Center for flow cytometry and confocal microscopy resources and T. Maniatis for advice. Z.D. is supported by an American Heart Association postdoctoral fellowship (grant no.20POST35220040). Postdoctoral fellowship support for T.X.J. is provided by the NIH (grant no.